acarbose vs miglitol
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of acarbose and miglitol. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Acarbose is a medicine that helps lower blood sugar levels in people with type 2 diabetes. It works best when used with diet and exercise.
Miglitol (Glyset) helps control blood sugar in adults with type 2 diabetes. It should be used with diet and exercise.
Acarbose is used to help control blood sugar in adults with type 2 diabetes. You should use it along with a healthy diet and regular exercise. This medicine helps to keep your blood sugar from getting too high after you eat.
Miglitol treats type 2 diabetes. It helps lower your blood sugar levels after meals. You should use it along with a healthy diet and regular exercise to manage your diabetes.
Acarbose slows down the digestion of carbohydrates (sugars and starches) in your body. It does this by blocking certain enzymes in your small intestine that break down carbs. This helps to prevent a sharp rise in blood sugar after meals.
Miglitol slows down the digestion of carbohydrates. This helps to prevent a large rise in blood sugar after you eat. It works in your gut to block certain enzymes.
- • Gas
- • Diarrhea
- • Abdominal pain
- • Gas
- • Diarrhea
- • Abdominal pain
- Hypoglycaemia 269
- Nausea 203
- Blood Glucose Increased 200
- Dizziness 160
- Diarrhoea 147
- Hypoglycaemia 67
- Hepatic Function Abnormal 46
- Decreased Appetite 39
- Diarrhoea 37
- Renal Impairment 37
You should not take acarbose if you have diabetic ketoacidosis or cirrhosis. Also, do not take it if you have inflammatory bowel disease, colon ulcers, or any bowel obstruction. This medicine can cause liver problems in some people. Tell your doctor right away if you develop symptoms like yellowing of the skin or eyes.
No specific warnings noted.
Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if acarbose will harm your unborn baby. Talk to your doctor if you are breastfeeding or plan to breastfeed. It is not known if acarbose passes into breast milk.
There is not enough information about the safety of miglitol during pregnancy or breastfeeding. Talk to your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.
How to Read This acarbose vs miglitol Comparison
acarbose is classified in the Alpha-Glucosidase Inhibitor drug class, while miglitol sits within the Alpha-Glucosidase Inhibitor class. Because both drugs share the same classification, they are often considered interchangeable in theory, but clinical outcomes rarely track that cleanly. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, acarbose has 979 submissions while miglitol has 226. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for acarbose or miglitol.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.